Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe.

Prendergast AJ, Berejena C, Pimundu G, Shonhai A, Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Cook AD, Spyer MJ, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Klein N, Walker AS.

AIDS. 2019 Apr 16. doi: 10.1097/QAD.0000000000002231. [Epub ahead of print]

PMID:
31008797
2.

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.

Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaav0537. doi: 10.1126/scitranslmed.aav0537.

PMID:
30944164
3.

Perceptions of Strategies and Intervention Approaches for HIV Self-Management among Ugandan Adolescents: A Qualitative Study.

Mutumba M, Mugerwa H, Musiime V, Gautam A, Nakyambadde H, Matama C, Stephenson R.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218823246. doi: 10.1177/2325958218823246.

PMID:
30798668
4.

Perceptions of HIV Self-Management Roles and Challenges in Adolescents, Caregivers, and Health Care Providers.

Mutumba M, Musiime V, Mugerwa H, Nakyambadde H, Gautam A, Matama C, Stephenson R.

J Assoc Nurses AIDS Care. 2018 Dec 18. doi: 10.1097/JNC.0000000000000007. [Epub ahead of print]

PMID:
30589651
5.

Utilization of "prevention of mother-to-child transmission" of HIV services by adolescent and young mothers in Mulago Hospital, Uganda.

Mustapha M, Musiime V, Bakeera-Kitaka S, Rujumba J, Nabukeera-Barungi N.

BMC Infect Dis. 2018 Nov 14;18(1):566. doi: 10.1186/s12879-018-3480-3.

6.

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.

Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Sarah Walker A, Thiebaut R, Klein N; CHAPAS-3 Trial Team .

J Infect Dis. 2019 Jan 1;219(1):89-100. doi: 10.1093/infdis/jiy495.

7.

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.

Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR, Lallemant M, Gibb DM.

J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S40-S48. doi: 10.1097/QAI.0000000000001748.

8.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.

Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpantmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group.

PLoS One. 2018 Apr 23;13(4):e0196239. doi: 10.1371/journal.pone.0196239. eCollection 2018.

9.

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.

Mallewa J, Szubert AJ, Mugyenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, Melly B, Mudzingwa S, Kelly C, Agutu C, Wilkes H, Nkomani S, Musiime V, Lugemwa A, Pett SL, Bwakura-Dangarembizi M, Prendergast AJ, Gibb DM, Walker AS, Berkley JA; REALITY trial team.

Lancet HIV. 2018 May;5(5):e231-e240. doi: 10.1016/S2352-3018(18)30038-9. Epub 2018 Apr 10. Erratum in: Lancet HIV. 2018 Jul;5(7):e340.

10.

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.

Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, Musiime V, Musoro G, Chepkorir P, Agutu C, Mallewa J, Rajapakse C, Wilkes H, Hakim J, Mugyenyi P, Walker AS, Gibb DM, Pett SL; Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team .

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139. doi: 10.1093/cid/cix1141.

11.

Beyond clinical trials: Cross-sectional associations of combination antiretroviral therapy with reports of multiple symptoms and non-adherence among adolescents in South Africa.

Natukunda HPM, Cluver LD, Toska E, Musiime V, Yakubovich AR.

S Afr Med J. 2017 Oct 31;107(11):965-975. doi: 10.7196/SAMJ.2017.v107i11.12405.

12.

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.

Szubert AJ, Prendergast AJ, Spyer MJ, Musiime V, Musoke P, Bwakura-Dangarembizi M, Nahirya-Ntege P, Thomason MJ, Ndashimye E, Nkanya I, Senfuma O, Mudenge B, Klein N, Gibb DM, Walker AS; ARROW Trial Team.

PLoS Med. 2017 Nov 14;14(11):e1002432. doi: 10.1371/journal.pmed.1002432. eCollection 2017 Nov.

13.

Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.

Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, Kityo C, Musiime V, Palumbo P, Schoffelen A, Sophan S, Zanoni B, Rinke de Wit TF, Calis JCJ, Sigaloff KCE; Paediatric Second-line Study Group.

J Int AIDS Soc. 2017 Sep 15;20(1):21930. doi: 10.7448/IAS.20.1.21930.

14.

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.

Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugyenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team.

N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822.

15.

Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.

Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry G, Penazzato M.

J Int AIDS Soc. 2017 Jun 27;20(1):21552. doi: 10.7448/IAS.20.1.21552. Review.

16.

Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.

Kityo C, Boerma RS, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, Boender TS, Mugyenyi PN, Rinke de Wit TF.

J Antimicrob Chemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188.

17.

Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.

Kekitiinwa A, Szubert AJ, Spyer M, Katuramu R, Musiime V, Mhute T, Bakeera-Kitaka S, Senfuma O, Walker AS, Gibb DM; ARROW Trial Team.

Pediatr Infect Dis J. 2017 Jun;36(6):588-594. doi: 10.1097/INF.0000000000001505.

18.

Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda.

Orikiiriza J, Nakawesi J, Kikaire B, Turitwenka D, Schlech W, Kambugu A, Lamorde M, Normark J, Hennessy M, Musiime V, Rujumba J, Ndeezi G, Tumwesigye NM, Doherty DG, Achan J.

AIDS. 2017 May 15;31(8):1196-1199. doi: 10.1097/QAD.0000000000001436. No abstract available.

PMID:
28441178
19.

Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team.

Int Health. 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.

20.

Psychological distress among Ugandan adolescents living with HIV: Examining stressors and the buffering role of general and religious coping strategies.

Mutumba M, Bauermeister JA, Harper GW, Musiime V, Lepkowski J, Resnicow K, Snow RC.

Glob Public Health. 2017 Dec;12(12):1479-1491. doi: 10.1080/17441692.2016.1170871. Epub 2016 Apr 11.

PMID:
28278753
21.

Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial.

Dirajlal-Fargo S, Musiime V, Cook A, Mirembe G, Kenny J, Jiang Y, Debanne S, Klein N, McComsey GA.

Pediatr Infect Dis J. 2017 Aug;36(8):761-767. doi: 10.1097/INF.0000000000001544.

22.

Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.

Abongomera G, Cook A, Musiime V, Chabala C, Lamorde M, Abach J, Thomason M, Mulenga V, Kekitiinwa A, Colebunders R, Kityo C, Walker AS, Gibb DM.

AIDS Behav. 2017 Feb;21(2):441-449. doi: 10.1007/s10461-016-1582-8.

23.

Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.

Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ.

J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: J Trop Pediatr. 2016 Oct 15;:null.

PMID:
27634175
24.

Examining the relationship between psychological distress and adherence to anti-retroviral therapy among Ugandan adolescents living with HIV.

Mutumba M, Musiime V, Lepkwoski JM, Harper GW, Snow RC, Resnicow K, Bauermeister JA.

AIDS Care. 2016 Jul;28(7):807-15. doi: 10.1080/09540121.2015.1131966. Epub 2016 Jan 10.

PMID:
27294696
25.

Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.

Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team.

J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.

26.

Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.

Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, Baptiste D, Walker AS, Gibb DM, Judd A.

Antivir Ther. 2016;21(7):579-585. doi: 10.3851/IMP3054. Epub 2016 Apr 29.

27.

Once vs twice-daily abacavir and lamivudine in African children.

Musiime V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, Mhute T, Cook A, Mugarura L, Munjoma M, Thoofer NK, Ndashimye E, Nankya I, Spyer MJ, Thomason MJ, Snowden W, Gibb DM, Walker AS; ARROW Trial Team.

AIDS. 2016 Jul 17;30(11):1761-70. doi: 10.1097/QAD.0000000000001116.

28.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team.

BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.

29.

Can abacavir be used safely in children without HLA testing?

Musiime V, Prendergast AJ.

Lancet HIV. 2016 Feb;3(2):e58-9. doi: 10.1016/S2352-3018(15)00228-3. Epub 2015 Dec 7. No abstract available.

PMID:
26847224
30.

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.

Kityo C, Sigaloff KC, Sonia Boender T, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugyenyi PN.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11.

31.

Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips A, Katabira E, Musiime V, Gilks C, Chan A, Hakim J, Colebunders R, Kityo C, Gibb DM, Seeley J, Ford D; Lablite Project Team.

BMC Health Serv Res. 2015 Nov 28;15:527. doi: 10.1186/s12913-015-1194-4.

32.

Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy.

Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I.

Pediatr Infect Dis J. 2016 Mar;35(3):e85-8. doi: 10.1097/INF.0000000000000997.

33.

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team.

Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.

34.

Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda.

Gleason B, Mirembe G, Namuyonga J, Okello E, Lwabi P, Lubega I, Lubega S, Musiime V, Kityo C, Salata RA, Longenecker CT.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):196-9. doi: 10.1097/QAI.0000000000000827.

35.

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.

Musoke P, Szubert AJ, Musiime V, Nathoo K, Nahirya-Ntege P, Mutasa K, Williams DE, Prendergast AJ, Spyer M, Walker AS, Gibb DM; ARROW Trial Team.

AIDS. 2015 Aug 24;29(13):1623-1632. doi: 10.1097/QAD.0000000000000749.

36.

Disclosure of HIV Status to Perinatally Infected Adolescents in Urban Uganda: A Qualitative Study on Timing, Process, and Outcomes.

Mutumba M, Musiime V, Tsai AC, Byaruhanga J, Kiweewa F, Bauermeister JA, Snow RC.

J Assoc Nurses AIDS Care. 2015 Jul-Aug;26(4):472-84. doi: 10.1016/j.jana.2015.02.001. Epub 2015 Feb 12.

PMID:
26066697
37.

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.

Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team.

AIDS. 2015 Mar 13;29(5):609-18. doi: 10.1097/QAD.0000000000000590.

38.

Psychosocial challenges and strategies for coping with HIV among adolescents in Uganda: a qualitative study.

Mutumba M, Bauermeister JA, Musiime V, Byaruhanga J, Francis K, Snow RC, Tsai AC.

AIDS Patient Care STDS. 2015 Feb;29(2):86-94. doi: 10.1089/apc.2014.0222. Epub 2015 Jan 21.

39.

Development of a psychosocial distress measure for Ugandan adolescents living with HIV.

Mutumba M, Resnicow K, Bauermeister JA, Harper GW, Musiime V, Snow RC, Lepkowski JM.

AIDS Behav. 2015 Feb;19(2):380-92. doi: 10.1007/s10461-014-0973-y.

PMID:
25577026
40.

Opportunities for improving the efficiency of paediatric HIV treatment programmes.

Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugyenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahirya-Ntege P, Walker AS, Sculpher MJ, Gibb DM.

AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.

41.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team.

Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.

42.

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.

Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, Young N, Opilo W, Lallemant M, Walker AS, Burger D, Gibb DM.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):148-54. doi: 10.1097/QAI.0000000000000135.

PMID:
24828266
43.

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.

Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Komunyena J, Kabamba D, Asiimwe AR, Mirembe G, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Walker SA, Klein N, Gibb DM; CHAPAS-3 trial team.

Antivir Ther. 2014;19(3):269-76. doi: 10.3851/IMP2695. Epub 2013 Oct 25.

PMID:
24717427
44.

HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.

Jaganath D, Walker AS, Ssali F, Musiime V, Kiweewa F, Kityo C, Salata R, Mugyenyi P; DART Trial; ARROW Trial.

AIDS Res Hum Retroviruses. 2014 Jun;30(6):523-30. doi: 10.1089/aid.2013.0255. Epub 2014 Feb 7.

45.

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ.

N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.

46.

Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.

Sebunya R, Musiime V, Kitaka SB, Ndeezi G.

AIDS Res Ther. 2013 Nov 11;10(1):25. doi: 10.1186/1742-6405-10-25.

47.

Does the CHER trial open up new therapeutic perspectives?

Colebunders R, Musiime V.

Lancet. 2013 Nov 9;382(9904):1539-40. doi: 10.1016/S0140-6736(13)61717-1. No abstract available.

PMID:
24209812
48.

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team.

PLoS Med. 2013 Oct;10(10):e1001542. doi: 10.1371/journal.pmed.1001542. Epub 2013 Oct 29.

49.

Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.

Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Kaudha E, Mukuye A, Matama C, Nankya I, Nakatudde L, Dekker JT, Hamers RL, Mugyenyi P, Rinke De Wit TF, Kityo C.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):925-30. doi: 10.1089/AID.2012.0218. Epub 2013 Apr 17.

PMID:
23517497
50.

Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe.

Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, Musoke P, Gibb DM; ARROW Trial Team.

Pediatr Infect Dis J. 2013 Aug;32(8):856-62. doi: 10.1097/INF.0b013e31828c3991.

PMID:
23407100

Supplemental Content

Loading ...
Support Center